Clinical Trials
6
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of K-645 in the Treatment of Multiple Migraine Attacks
- Conditions
- Acute Migraine
- Interventions
- Drug: PlaceboDrug: K-645 dose level 1Drug: K-645 dose level 2
- First Posted Date
- 2025-08-11
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Kallyope Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT07116499
- Locations
- 🇺🇸
Clinical Research Institute, Minneapolis, Minnesota, United States
🇺🇸Headache Wellness Center, Greensboro, North Carolina, United States
🇺🇸DM Clinical Research - Bellaire, Houston, Texas, United States
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
- Conditions
- Acute Migraine
- Interventions
- Drug: Elismetrep (K-304) Dose Level 1Drug: Elismetrep (K-304) Dose level 2Drug: Elismetrep (K-304) Dose level 3Drug: Elismetrep (K-304) Dose level 4Drug: Placebo
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Kallyope Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT06848075
- Locations
- 🇺🇸
Central Research Associates, LLC (CRA) dba Flourish Research, Birmingham, Alabama, United States
🇺🇸AMR Mobile, Mobile, Alabama, United States
🇺🇸Wake Research/ Tucson Neuroscience Research, Tucson, Arizona, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus (T2DM)Obesity
- Interventions
- Drug: Matching placebo to K-757 and K-833 QDDrug: K-757 and K-833 QDDrug: Matching placebo to K-757 and K-833 BIDDrug: K-757 and K-833 BID
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Kallyope Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT06305351
- Locations
- 🇺🇸
QPS Miami, Miami, Florida, United States
A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833
- Conditions
- Obesity
- Interventions
- Drug: K-757 120 mg BID and K-833 100 mg BIDDrug: K-757 120 mg BID and matching placebo to K-833Drug: Matching placebo to K-757 and matching placebo to K-833
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Kallyope Inc.
- Target Recruit Count
- 155
- Registration Number
- NCT06019559
- Locations
- 🇺🇸
Artemis Institute for Clinical Research, LLC, San Diego, California, United States
🇺🇸Clinical Research Atlanta, Stockbridge, Georgia, United States
🇺🇸Cotton O'Neil Clinical Research Center, Topeka, Kansas, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers
- Conditions
- Obesity
- Interventions
- Drug: K-757 and K-833Drug: Matching placebo to K-757Drug: Matching placebo to K-757 and matching placebo to K-833Drug: Matching placebo to K-757, open-label sitagliptinDrug: K-757 and open-label sitagliptin
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Kallyope Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05900531
- Locations
- 🇺🇸
ProSciento, Inc., Chula Vista, California, United States
- Prev
- 1
- 2
- Next